Clinuvel Pharmaceuticals Ltd.
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic…
1D
+3.6%
1W
-6.3%
1M
-11.2%
6M
–
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
23/02/2027 (in 129 days)
Volatility around earnings
~60% stronger price swings than usual
FREE FLOAT
83.3%
FLOAT SHARES
42,060,397
AVG. DAILY VOLUME (30D)
13,888
Clinuvel Pharmaceuticals Ltd. is a company in the Healthcare sector, Medical - Pharmaceuticals industry, headquartered in Australia.
The IPO was on 13/07/2026; the stock trades on NASDAQ under the ticker CUVL.
The next earnings date is 23/02/2027.
Around past earnings, price swings were roughly 60% stronger than usual.
Yes. The last dividend was US$0.04 per share, ex-date 08/09/2026, paid on 28/09/2026.
Comparable stocks include Corcept Therapeutics, Liquidia, Latigo Biotherapeutics, Helus Pharma, Eli Lilly and Company, Johnson & Johnson, AbbVie and Merck &.
Clicking "Analyze stock" lets five strategies assess Clinuvel Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.